In pancreatic cancer cells, as a representative KRAS-mutated tumor entity, targeting WEE1 induced sensitization to radiation with a DER of 1.3 ± 0.1 in MiaPaCa-2 cells and gemcitabine chemoradiation in vitro and in vivo through inhibition of the HR repair pathway and abrogation of the G2 checkpoint [105], [106]. This evidence concerns the gene KRAS and pancreatic neoplasm.